Did Wegovy work for you — and what does the evidence say it should do?

What the STEP 1 trial results actually looked like across participants

The headline from STEP 1 is an average, and averages flatten a real distribution. In that 68-week randomised trial, participants on semaglutide 2.4mg lost a mean of around 15% of body weight, but the range ran from very modest losses to well above 20%. Roughly a third of participants lost 20% or more, while a proportion lost under 10%. NICE's own appraisal of semaglutide notes this variability and builds in a decision point: if less than 5% weight loss has occurred after six months on the maintenance dose, continuing the medicine should be reviewed. That threshold is not a failure flag so much as a signal to have a prescriber conversation.

The most consistent predictor of a good response is reaching and tolerating the maintenance dose. Many people who find early results slow are still titrating upward; 2.5mg or 0.5mg starter doses are not therapeutic targets, they are the body's adjustment period. The trajectory often changes meaningfully once the full 2.4mg dose is established.

A question our prescribers hear most weeks is whether a slow start means the medicine is not going to work at all. The honest answer is: not necessarily. Gastrointestinal side effects in early weeks can limit food intake in ways that feel dramatic but then settle, making the appetite-reducing effect of the medicine itself clearer once the dose is stable. The NICE appraisal of semaglutide (TA875) provides a useful framework for thinking about what a meaningful response looks like and over what timeframe.

Why Wegovy works differently for different people

Semaglutide is a GLP-1 receptor agonist. It slows gastric emptying, amplifies fullness signals and reduces appetite, but the strength of those effects varies with individual physiology. Factors that genuinely influence outcome include starting BMI, metabolic health, the presence of conditions such as insulin resistance or type 2 diabetes, how well side effects are tolerated (which determines whether the full dose is reached), and how consistently the lifestyle component (reduced-calorie eating and regular activity) is maintained alongside treatment.

Hormonal factors matter too. People going through or past menopause, or managing thyroid conditions, may find weight loss slower not because semaglutide is failing but because other biology is pushing back. That does not mean the medicine is not working; it means the conversation with a prescriber needs to be broader. The NHS semaglutide medicines page sets out how the medicine works and what to expect at each stage of treatment.

There is also a group of people for whom GLP-1 medicines genuinely produce a modest response regardless of adherence. Research into why is ongoing. For now, prescribers use the six-month review as the evidence-based checkpoint: enough time on a stable dose to give a fair assessment, not so long that someone continues a medicine that is not serving them.

If you are asking why Wegovy did not work for you, there is a specific set of questions worth working through with a clinician before drawing conclusions.

The 7.2mg dose and what it changes

In January 2026 the MHRA approved a higher maintenance dose of semaglutide (7.2mg weekly) and on 14 April 2026 approved a dedicated single-dose 7.2mg pen. Trials reported around 20.7% average weight loss over 72 weeks at this dose, narrowing the gap considerably with tirzepatide's results. That is a meaningful step up from the 2.4mg data and is worth knowing if your own result at the lower dose felt modest.

The 7.2mg licence applies to adults with a BMI of 30 or above. Titration still starts at 0.25mg; the higher ceiling does not change the starting point or the pace of dose increases, both of which remain clinically determined. Whether the 7.2mg option is appropriate for any individual is a prescriber decision, not a self-directed one. If you are wondering when results typically appear or how the titration schedule affects the timeline, that question has a more detailed answer worth reading alongside this one.

Thinking about whether Wegovy is likely to work for you specifically involves more than BMI alone, it is the conversation a clinical assessment is designed to have. You can also read about how semaglutide works week by week if you want the mechanism spelled out clearly.

Getting the most from treatment and knowing when to reassess

Wegovy is licensed alongside a reduced-calorie diet and increased physical activity, not as a standalone intervention. The trial participants who achieved the strongest results were in a structured lifestyle support programme. That does not mean you need a gym membership; it means protein intake, hydration and some form of regular movement make a real difference to both the rate and the quality of weight lost. Exercise while taking Wegovy is not just safe for most people, it tends to improve how the treatment feels too.

If you are at the review stage and results have been modest, the options include continuing with prescriber support, considering whether the 7.2mg dose is appropriate, or exploring whether a different treatment might be a better fit. The semaglutide overview and the broader Wegovy treatment page cover the evidence across all doses. For a sense of how others describe their experience, Wegovy feedback reflects a realistic range of outcomes rather than curated success stories.

If you are considering starting treatment for the first time, or are mid-course and want a clinical conversation, the free consultation at nume is reviewed the same day by a GPhC-registered prescriber, a real clinician who reads your answers and makes a clinical judgement, not a scoring algorithm. Check your eligibility and begin there.